Outcomes

Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ

Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw

Menopause and Rheumatoid Arthritis: Are we asking enough? A study from Mayo Clinic at ACR Convergence, abstract 1849 examines menopause symptom burden in women with and without RA. Using two research datasets, Kristen Young and colleagues conducted a cross-sectional analysis of https://t.co/V3VJXo3z5w

Might stem cells actually work in knee OA?? Possibly, only the right combo 🇰🇷 OSCA: OS (allo mesenchymal stem cells) + CAM (cartilage acellular matrix) anti-inflamm, structural, pain ph2a impressive signal over placebo & maybe tissue repair, benefit out to 5y? #ACR26 @RheumNow https://t.co/PU3MUqxH7Q

https://x.com/drdavidliew/status/2120649383033397441/photo/1

Is 60-40-20 broken? RA trial rule of thumb: roughly 60%-40%-20% for ACR20-50-70 girocitinib (JAK1/Tyk2) vs tofacitinib ACR20: 91% vs 75% ACR50: 73% vs 49% ACR70: 44% vs 25% there will be debate (all in China, tofa exposure) but what a meeting for H2H ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg

https://x.com/drdavidliew/status/2120645121083633898/photo/1

ACR26 summary, gut joint axis: replenishing TRBV9 CD8 T cells, a dual targeting antibody, calprotectin for gut inflammation, and outcomes of joint gastroenterology and rheumatology meetings. @rheumnow #ACR26 Abstract#1027 Abstract#2941 Abstract#1336 Abstract#2287

@RheumNow #2. Abstract 1876. A consensus-driven core outcome set for healthcare transition in adolescents and young adults with JIA identifies 10 outcomes spanning the Quadruple Aim framework: Population health, experience of care, cost of care, provider experience. #ACR2026

Reflection on sequencing: antibody status and patient factors predicted outcome more than mechanism, TNFi cycling was the most common switch in the last 2 decades, and Leeds data suggest some treatment failure may be iatrogenic. @rheumnow #ACR26 Abstract#2284 Abstract#1324

Single ctr retros study Inadeq response (IR) to DEN 37 pts had IR In IR who developed fractures, incr prev of prior vertebral fractures, older age, low fem BMD, incr GIOP In all IR pts, incr CTx values during DEN tx lack of specific criteria for DEN-IR @RheumNow #ACR26 Abs2957 https://t.co/Oxg2k4OSdT

(2/2) LB22 Both DAZ arms with similar AEs compared to placebo group Signal for symptom response at 4W? Improved pt reported sicca outcomes with 1500mg Q4W dose vs placebo @RheumNow #ACR26

Abstract 2928: what is the relationship between frailty and new onset geriatric syndromes? Vs robust (non-frail), - frailty incr odds of disability in ADL (HR 2.79), mobility (2.78), IADL (1.73), loss of indep (2.31), & dementia (1.71) - also seen in pre-frail @RheumNow #ACR26 https://t.co/qEjO7pNcud

Is Obesity Inflating Your Disease Activity Scores? Dr. Michael George, MD, MSCE, will take on that question in the session "Size Matters: Optimizing Therapy and Outcomes for Patients with Obesity and Rheumatic Disease" https://t.co/ZS5dQSZVUj https://t.co/D5ekNiRxQu

Is Obesity Inflating Your Disease Activity Scores? | RheumNow

Spanish retrospective study by Funcia et al on DEN discontinuation & fracture incidence 7% developed fractures after DEN dc Incr fall risk was the only significant factor identified Causes of discontinuation: Poor adherence, other causes & AEs @RheumNow #ACR26 Abs2956 https://t.co/lSSJMrxVuk

Telehealth RA visits rely on patient-led joint counts, but physician-patient agreement on SJ is weakest (ICC 0.28 vs 0.51 for TJ). Low-cost hand model + 5min video raised patient confidence checking SJ (median 3 to 4, p<0.01). Accuracy untested. A#2965 @RheumNow #ACR26 https://t.co/8Sgx0Adxkn

https://x.com/JihaRheum/status/2120563202878836977/photo/1

Real-world data fr Northern Ireland (Banford et al) of Romosozumab for severe OP Pop’n: 22 pts, QRISK 3 scores; no prior MI/stroke Romo showed sinificant improvement in BMD w/n 12 mos; modest in the hip and higher improvement on lumbar spine BMDs @RheumNow #ACR26 Abs2953 https://t.co/PZcjbRVdTv

ASAS points to consider for difficult to manage, including treatment refractory, axSpA: 4 overarching principles and 10 points, endorsed by 91.3% of ASAS members. Key finding: recommends reassessing diagnosis, confirming inflammation, checking adherence and comorbidities before https://t.co/2JXibesxBm

@RheumNow AI-driven SDOH screening and intervention: Studies are leveraging automation and machine learning to identify unmet social needs and facilitate referrals. Can AI help bridge the gap between screening and action? #ACR2026 Determinates of health and outcomes #5

Higher orosomucoid-1 levels were associated with future difficult-to-treat RA in two cohorts (n=198). Samples were taken years before D2T criteria were met. Independent validation using ELISA showed an AUC of 0.86. #2933 @Rheumnow #ACR26

Can We Predict Work Disability in Lupus? When it comes to managing patients with SLE there are many aspects of the disease to consider – disease activity, organs involved, and the potential for long term damage. Given that SLE affects many working-age adults, there is another https://t.co/9Fp4MxKpw9

@RheumNow Social determinants of health (SDOH) in rheumatology: Are we routinely screening for SDOH, and more importantly, how are we addressing the unmet needs identified? #ACR2026 Determinates of health and outcomes in rheumatic diseases #4

Better RA therapies have not had an impact on diabetes risk. In 23,956 incident RA cases vs 185,361 controls, diabetes risk was 17% higher after adjustment, with no improvement in relative risk over time. #2927 #ACR26 @Rheumnow https://t.co/2l0dDgygdL

https://x.com/DrMiniDey/status/2120543825173131390/photo/1

In this cohort study on tx persistence by Dr Sari et al, patients w/biologic naive axSpA who started their 1st biologics show that pts who started w/n 5 yrs had 30% lower risk of stopping their 1st biologic (maj. of pts received TNFis) @RheumNow #ACR26 Abs2945 https://t.co/OzQTrmZ9Yt

https://x.com/RHEUMarampa/status/2120543311861604633/photo/1

@RheumNow Determinates of health and outcomes in Rheumatic diseases #3. Race & ethnicity in rheumatology guidelines: Clarify their role in recommendations, improve trial diversity to strengthen evidence, and do not restrict treatment options based on race or ethnicity. #ACR26

Provocative conclusions from study of secular trends in GCA mortality 1. Exciting decline in age-adjusted mortality rate from 1999-2019, average annual percentage change of -5.43% per year 2. Plateau & uptick around 2020 Authors suggest inadequate disease control in TCZ era as https://t.co/rB6iFkamaH

https://x.com/EBRheum/status/2120540301903487448/photo/1

@RheumNow Determinates of health and outcomes in Rheumatic diseases #2. Lupus nephritis & race: Evidence to support racial/ethnic differences in Rx efficacy is limited. ACR 2024 guidelines do NOT recommend basing treatment decisions on race or ethnicity. #ACR26

Topics

Daily Download

The Spectrum of RA

Podcasts

Topic Videos

Do you get our email newsletter?